Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.059 CHF | +2.43% | +7.27% | +43.90% |
Apr. 17 | Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis | MT |
Apr. 17 | Swiss Court OKs Moratorium Extension for Spexis | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+43.90% | 4.27M | |
-2.68% | 85.68B | |
+4.08% | 41.4B | |
-25.35% | 28.22B | |
+54.31% | 24.64B | |
-4.52% | 16.98B | |
-42.09% | 13.29B | |
-17.77% | 11.66B | |
-12.10% | 11.65B | |
+0.75% | 8.18B |
- Stock Market
- Equities
- POLN Stock
- News Spexis AG
- Polyphor : to Commence UK Clinical Trial for Inhaled Antibiotic Murepavadin